Cathflo buyout


Intravenous products: Roche has announced that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for US$86.50 per share.

Genentech are the manufacturers of Cathflo® Activase® (Alteplase) which is indicated for the restoration of function to central venous access devices (CVADs) as assessed by the ability to withdraw blood.

Click here for the full news story.

More IV news at IVTEAM


Comments are closed.